These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35882674)

  • 21. Mechanistic understanding of underperforming enteric coated products: Opportunities to add clinical relevance to the dissolution test.
    Amaral Silva D; Davies NM; Doschak MR; Al-Gousous J; Bou-Chacra N; Löbenberg R
    J Control Release; 2020 Sep; 325():323-334. PubMed ID: 32649973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions.
    Hofmann M; García MA; Al-Gousous J; Ruiz-Picazo A; Thieringer F; Nguyen MA; Månsson W; Galle PR; Langguth P
    Eur J Pharm Biopharm; 2020 Apr; 149():229-237. PubMed ID: 32112894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of Diluted Compendial Media as Dissolution Test Solutions with Low Buffer Capacity for the Investigation of Dissolution Rate of Highly Soluble Immediate Release Drug Products.
    Yoshida H; Abe Y; Tomita N; Izutsu KI
    Chem Pharm Bull (Tokyo); 2020; 68(7):664-670. PubMed ID: 32612001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo predictive dissolution: transport analysis of the CO2 , bicarbonate in vivo buffer system.
    Krieg BJ; Taghavi SM; Amidon GL; Amidon GE
    J Pharm Sci; 2014 Nov; 103(11):3473-3490. PubMed ID: 25212721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs.
    McNamara DP; Whitney KM; Goss SL
    Pharm Res; 2003 Oct; 20(10):1641-6. PubMed ID: 14620520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matching phosphate and maleate buffer systems for dissolution of weak acids: Equivalence in terms of buffer capacity of bulk solution or surface pH?
    Cristofoletti R; Dressman JB
    Eur J Pharm Biopharm; 2016 Jun; 103():104-108. PubMed ID: 27032508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FaSSIF-V3, but not compendial media, appropriately detects differences in the peak and extent of exposure between reference and test formulations of ibuprofen.
    Cristofoletti R; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():134-40. PubMed ID: 27287554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.
    Karkossa F; Klein S
    J Pharm Pharmacol; 2017 Oct; 69(10):1327-1340. PubMed ID: 28703304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates.
    Litou C; Vertzoni M; Xu W; Kesisoglou F; Reppas C
    Eur J Pharm Biopharm; 2017 Jun; 115():94-101. PubMed ID: 28214603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity.
    Radwan A; Amidon GL; Langguth P
    Biopharm Drug Dispos; 2012 Oct; 33(7):403-16. PubMed ID: 22782559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.
    Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW
    Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases.
    Krieg BJ; Taghavi SM; Amidon GL; Amidon GE
    J Pharm Sci; 2015 Sep; 104(9):2894-904. PubMed ID: 25980464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.
    Hens B; Tsume Y; Bermejo M; Paixao P; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Loebenberg R; Lee A; Frances A; Amidon G; Yu A; Benninghoff G; Salehi N; Talattof A; Sun D; Amidon GL
    Mol Pharm; 2017 Dec; 14(12):4281-4294. PubMed ID: 28737409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model.
    Jede C; Wagner C; Kubas H; Weigandt M; Weber C; Lecomte M; Badolo L; Koziolek M; Weitschies W
    Mol Pharm; 2019 Sep; 16(9):3938-3947. PubMed ID: 31335153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. pH-Dependent Solubility and Dissolution Behavior of Carvedilol--Case Example of a Weakly Basic BCS Class II Drug.
    Hamed R; Awadallah A; Sunoqrot S; Tarawneh O; Nazzal S; AlBaraghthi T; Al Sayyad J; Abbas A
    AAPS PharmSciTech; 2016 Apr; 17(2):418-26. PubMed ID: 26202065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.